Pregnancy Clinical Trial
Official title:
Outpatient Foley Catheter Compared to Usual Inpatient Care for Cervical Ripening: a Randomized Controlled Trial
Induction of labor, or causing labor to start before it otherwise starts spontaneously, is
sometimes necessary as pregnancy progresses to ensure the safety of both mother and infant.
Labor induction often begins with cervical ripening, in which various methods are used to
prepare the cervix for contractions and labor. Cervical ripening is beneficial and decreases
the need for cesarean section; however, it can be a lengthy process. By tradition, pregnant
women are admitted to the hospital at the start of this process and remain inpatient until
after the baby is born.
There is increasing interest in allowing the mother to return to her own home during the very
first part of this process. She may be more satisfied in a more comfortable environment with
her family. Growing scientific evidence supports use of the Foley catheter as an approach to
outpatient cervical ripening. The Foley catheter is a safe, effective method that is already
used often in the inpatient setting. It does not cause increased health risks for either
mother or baby. Previous research studies have shown that it is just as safe and effective
when women return to their own homes with a Foley catheter and that women spend less time in
the hospital before delivery. More information is needed before this becomes a standard of
care. This research study will allow pregnant women to return home for the first night of
their labor induction with a Foley catheter in place. In the morning they will return to the
hospital and stay until after delivery. They will be compared to a group of women who remain
in the hospital for their entire labor induction. The benefits to going home during labor
induction may include increasing maternal satisfaction and optimizing the use of resources in
the hospital.
This study began as a randomized controlled trial, but due to difficulty enrolling and high
screen-failure rates, was modified to a prospective study design allowing participants to
choose the arm they wished to participate in at the time of providing informed consent. The
intervention group (both designs) was comprised of low risk pregnant women who will have a
Foley catheter placed followed by dismissal home with return in the morning for continuation
of the labor induction process. The control group consists of women (both designs) who will
remain inpatient during the entire cervical ripening phase followed by continuation of the
labor induction process in the inpatient setting.
Low risk pregnant women at term will be enrolled in clinic after their providers have
recommended induction of labor for a specific indication. They will be educated about
induction of labor, the Foley catheter, and the proposed research study. If they would like
to participate, they will be consented in the clinic. For the RCT design, a
computer-generated randomization would occur on the morning of the planned induction, and the
patients will be contacted by phone to inform them of their assigned group. The randomization
will be stratified by parity and BMI.
Outpatient Foley catheter group:
If the patient was randomized or chose the intervention group (outpatient Foley), she
underwent the following. She will present to the Family Birth Center in the evening at 1900.
She will undergo a nonstress test (NST), an ultrasound for fetal presentation and amniotic
fluid index, and a cervical exam with calculation of a Bishop score. The patient will be
asked if she is having regular, painful contractions, decreased fetal movement, vaginal
bleeding, leakage of fluid from the vagina concerning for rupture of membranes, or fevers or
chills. A Foley catheter will be placed if the following criteria have been met: the
nonstress test is reactive and reassuring (without the presence of ≥ 3 variable decelerations
in a 20 minute period, late-appearing decelerations, or any deceleration lasting ≥1 minute),
the fetal presentation is cephalic, the amniotic fluid index is 5 centimeters or more, the
Bishop score is <6, the cervical dilation is <3 cm, and she has no other clinical
characteristics that exclude her from the trial as described in the inclusion/exclusion
criteria. A 30 French Foley will be placed either digitally or with speculum assistance. It
will be inflated with 60 cc of normal saline and taped to the patient's inner thigh. The
fetal heart rate tracing will be monitored for 1 hour after Foley placement. The patient will
be sent home if the following criteria are met: the fetal heart rate tracing is reactive and
category I; there is no evidence of rupture of membranes, spontaneous labor, or vaginal
bleeding more than spotting; and no other exclusion criteria are present. Before discharge,
the patient may receive pharmacologic pain relief in the form of one dose of acetaminophen
and/or fentanyl.
The patient will be instructed to return to the Family Birth Center at 0700 the following
day. She will be given detailed verbal and written instructions of when to contact and return
to the Family Birth Center before the morning. She will be provided with the 24 hour direct
access line for the Family Birth Center to call with any questions or concerns. If the Foley
catheter is expulsed at home, she is to record the time of expulsion. She does not need to
return to the Family Birth Center earlier than planned due to expulsion.
When the patient returns in the morning, the induction will be continued at the discretion of
the providing obstetric team. The remainder of her care during the first, second, and third
stages of labor will be at the discretion of the providing team. The patient will have
continuous fetal monitoring. All patients' labor progress will be monitored using a
partogram. Cesarean delivery will not be performed for arrest of labor or failed induction
unless all criteria have been met as outlined by the Family Birth Center Workgroup protocol
made effective 6/2/14.
Inpatient usual care group:
If the patient was randomized or chose the control group (inpatient usual care), she will
arrive to the Family Birth Center at 1900 to undergo induction of labor. She will undergo a
nonstress test (NST), an ultrasound for fetal presentation and amniotic fluid index, and a
cervical exam with calculation of a Bishop score. The patient will be asked if she is having
regular, painful contractions, decreased fetal movement, vaginal bleeding, leakage of fluid
from the vagina concerning for rupture of membranes, or fevers or chills. She will be
included or excluded from the study based on the above information. Induction of labor may
proceed at the discretion of the providing obstetric team. Cervical ripening should be
performed with either 25 mcg vaginal misoprostol every 4 hours with a maximum of six doses or
a 30 Fr Foley catheter filled with 60 cc normal saline. The patient may need both methods
during her inpatient stay if her cervix is unfavorable. A Foley catheter will be favored
during the cervical ripening phase if there is tachysystole and/or a nonreassuring fetal
heart tracing precluding further misoprostol administration, provided the Bishop score is
still <6. The remainder of her care during the first, second, and third stages of labor will
be at the discretion of the providing team. All patients' labor progress will be monitored
using a partogram. Cesarean delivery will not be performed for arrest of labor or failed
induction unless all criteria have been met as outlined by the Family Birth Center Workgroup
protocol made effective 6/2/14.
Follow up
Each mother was asked to complete a survey before leaving the hospital describing her
experience and satisfaction with the cervical ripening process (both study designs. Primary
and secondary endpoints will be collected from neonatal and maternal charts through 42 days
after the patient's delivery or the date of the patient's final postpartum clinic visit,
whichever comes last.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02408315 -
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
|
Phase 3 |